News
EVOK
0.4750
+8.95%
0.0390
Weekly Report: what happened at EVOK last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at EVOK last week (0408-0412)?
Weekly Report · 04/15 11:47
Weekly Report: what happened at EVOK last week (0401-0405)?
Weekly Report · 04/08 11:53
Weekly Report: what happened at EVOK last week (0325-0329)?
Weekly Report · 04/01 11:50
Weekly Report: what happened at EVOK last week (0318-0322)?
Weekly Report · 03/25 11:53
Evoke Pharma Welcomes Matthew D’Onofrio as New CEO
TipRanks · 03/21 20:33
Evoke Pharma Taps Operating Chief D'Onofrio to Succeed CEO Gonyer
Evoke Pharma taps Matthew D'Onofrio to succeed David Gonyer as chief executive. The company says he is departing for personal reasons. D' onofrio will assume Gonye's board seat on March 31, effective March 31. The specialty pharmaceutical company is called Evoke Pharma.
Dow Jones · 03/21 20:25
Evoke Pharma names Matthew D’Onofrio as new CEO
Seeking Alpha · 03/21 20:21
*Evoke Pharma: D'Onofrio Will Assume Gonyer's Board Seat as of March 31 >EVOK
Dow Jones · 03/21 20:18
*Evoke Pharma: Gonyer's Departure Is for Personal Reasons >EVOK
Dow Jones · 03/21 20:17
*Evoke Pharma : Matthew D'Onofrio Will Be Succeeding David Gonyer as CEO as of March 31 >EVOK
Dow Jones · 03/21 20:17
*Evoke Pharma Announces Senior Leadership Transition With Promotion of Matthew J. D'Onofrio to CEO
Dow Jones · 03/21 20:17
Weekly Report: what happened at EVOK last week (0311-0315)?
Weekly Report · 03/18 11:51
EVOK Stock Earnings: Evoke Pharma Misses EPS, Beats Revenue for Q4 2023
Evoke Pharma reported earnings per share of -59 cents. The company reported revenue of $1.68 million. This was 2.82% better than the analyst estimate for revenue of -50 cents. Evoke Pharma was down 2.7% in after-hours trading.
Investorplace · 03/15 00:53
Evoke Pharma GAAP EPS of -$0.09 beats by $0.41, revenue of $7.3M
Seeking Alpha · 03/14 20:07
Press Release: Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
Evoke Pharma reports fourth quarter and full year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022 Company projects $14M in net revenue for 2024. The company is focused on treatments for gastrointestinal diseases with an emphasis on GIMOTI nasal spray.
Dow Jones · 03/14 20:05
Press Release: Evoke Pharma Reports Fourth -2-
Metoclopramide may cause potential adverse reactions including parkinsonism, depression, and suicide. Most common adverse reactions for GIMOTI are dysgeusia, headache, and fatigue. The company's business is subject to risks and uncertainties. Evoke Pharma Inc. Is a subsidiary of Evoke.
Dow Jones · 03/14 20:05
Earnings Scheduled For March 14, 2024
Pharming is projected to report earnings for its fourth quarter. Dick's Sporting Goods is expected to report quarterly earnings at $3.35 per share on revenue of $817.48 million. Other companies expected to release earnings before the bell include Hello Gr, Weibo and Build-A-Bear Workshop.
Benzinga · 03/14 09:52
Notable earnings after Thursday's close
Major earnings expected after the bell on Thursday include: Adobe, Ulta Beauty, Skillz and Wheaton Precious Metals Corp. Other notable earnings slated for release after Thursday's close include: ZUMZ, ULTA and Blink Charging Co. Other companies with major earnings scheduled after the close of business on Thursday.
Seeking Alpha · 03/13 21:35
Evoke Pharma Q4 2023 Earnings Preview
Evoke Pharma (NASDAQ:EVOK) is scheduled to announce Q4 earnings results on Thursday, March 14th. The consensus EPS Estimate is -$0.50 and the consensus revenue estimate is $1.63M. Evoke Pharma is expected to report its Q4 2023 earnings after market close.
Seeking Alpha · 03/13 21:35
More
Webull provides a variety of real-time EVOK stock news. You can receive the latest news about Evoke Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About EVOK
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.